Showing results (31-40 of 56) with videos related to
Sort By:
Pageof 6
NPJ Precision Oncology|May 20, 2025
Multimodal spatial proteomic profiling in acute myeloid leukemiaChristopher P Ly, Ivo Veletic, Christopher D Pacheco, et al.The Lancet. Haematology|August 12, 2019
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 studyFarhad Ravandi, Rita Assi, Naval Daver, et al.Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.Blood Advances|October 26, 2022
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLLNitin Jain, Jayastu Senapati, Beenu Thakral, et al.Proceedings of the National Academy of Sciences of the United States of America|January 13, 2019
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancerJorge Blando, Anu Sharma, Maria Gisela Higa, et al.Cancer Research Communications|August 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder CancerMatthew T Campbell, Amishi Y Shah, Pavlos Msaouel, et al.Nature Communications|November 5, 2021
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinomaMatthew T Campbell, Surena F Matin, Alda L Tam, et al.Science Translational Medicine|April 20, 2022
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapyPavlos Msaouel, Sangeeta Goswami, Peter F Thall, et al.Research Square|November 28, 2024
Safety outcomes and immunological correlates in a prospective clinical trial of immune checkpoint therapy plus debulking surgery for patients with metastatic renal cell carcinomaSangeeta Goswami, Jianjun Gao, Sreyashi Basu, et al.Nature Communications|February 21, 2025
Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trialSangeeta Goswami, Jianjun Gao, Sreyashi Basu, et al.Pageof 6